Journal article
Optimizing Statins and Ezetimibe in Guideline-Focused Management
Cardiology clinics, Vol.36(2), pp.221-223
05/2018
DOI: 10.1016/j.ccl.2017.12.003
PMID: 29609751
Abstract
Statins are essential medications in the management of patients with clinical atherosclerotic cardiovascular disease, and have been supported by numerous clinical trials. Emerging evidence suggests that adding ezetimibe to statin therapy is associated with a net benefit and improved hard clinical outcomes, particularly in patients with significantly elevated atherosclerotic cardiovascular disease risk and elevated low-density lipoprotein cholesterol levels.
Details
- Title: Subtitle
- Optimizing Statins and Ezetimibe in Guideline-Focused Management
- Creators
- Aref A Bin Abdulhak - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USAJennifer G Robinson - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- Cardiology clinics, Vol.36(2), pp.221-223
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ccl.2017.12.003
- PMID
- 29609751
- ISSN
- 0733-8651
- eISSN
- 1558-2264
- Grant note
- GlaxoSmithKline (https://doi.org/10.13039/100004330) Sanofi (https://doi.org/10.13039/100004339) Takeda Amarin Esai Esperion Regeneron (https://doi.org/10.13039/100009857) AstraZeneca (https://doi.org/10.13039/100004325) Pfizer (https://doi.org/10.13039/100004319) Eli Lilly Merck (https://doi.org/10.13039/100004334) Amgen (https://doi.org/10.13039/100002429)
- Language
- English
- Date published
- 05/2018
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995172902771
Metrics
27 Record Views